OraPro-EBV
Epstein-Barr Virus (EBV) Prevention
Pre-clinicalActive
Key Facts
About iosBio Pharma
iosBio Pharma is a private, pre-clinical stage biotech developing next-generation oral vaccines. Its core innovation is the OraPro™ platform, which enables needle-free, thermostable oral delivery, potentially eliminating cold-chain logistics and enabling global vaccine access. The company's lead candidate, OraPro-EBV, is preparing for Phase 1 trials, targeting EBV-associated diseases like multiple sclerosis and certain cancers. iosBio is currently seeking £12-30 million in funding to advance its lead program into clinical development.
View full company profile